依达拉奉对中度颅脑损伤的疗效评价

The clinical efficacy of edaravone on acute medium brain injury

目的观察依达拉奉对急性中度颅脑损伤的治疗效果。方法将78例中度颅脑损伤患者随机分为治疗组和对照组。治疗组在常规治疗的基础上,给予依达拉奉30mg加入生理盐水100ml静脉滴注,30分钟内滴定,每天2次,共用14天,总剂量840mg。记录两组病人治疗后3个月时的GOS评分。结果治疗后两组病人3个月时的GOS评分有差异,两组的不良反应无差异。结论依达拉奉对治疗中度颅脑损伤患者有一定疗效。

Objective To observe the efficacy of edaravone on the treatment of acute medium bruin injury. Methods A total of 78 patients with acute medium brain injury were divided into observe group and control group randomly. The control group was given a routine treatment of acute brain injure. The observe group was treated with edaravone in addition to the routine treatment received by the control group. The glasgow outcome scale （GOS） in the two groups were record after three months. Results There was significant difference between the two groups in the GOS after three months. There was no significant difference between the two groups in adverse reaction. Conclusion It is effective to use edaravone in treatment of acute medium brain injure.